To include your compound in the COVID-19 Resource Center, submit it here.

Bekinda: Completed Ph III GUARD enrollment

RedHill completed enrollment of 320 patients in the double-blind, placebo-controlled,

Read the full 103 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE